Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis

OBJECTIVES: Natalizumab (NTZ), a monoclonal antibody against very late antigen-4 (VLA-4), is one of the most efficient therapies to prevent acute relapses in multiple sclerosis (MS). VLA-4 is the key adhesion molecule for peripheral immune cells, especially lymphocytes to enter the CNS. While its bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisch, Esther S., Häusler, Darius, Weber, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Clinical/Scientific Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112857/
https://www.ncbi.nlm.nih.gov/pubmed/37072216
http://dx.doi.org/10.1212/NXI.0000000000200114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112857/
https://www.ncbi.nlm.nih.gov/pubmed/37072216
http://dx.doi.org/10.1212/NXI.0000000000200114

Ejemplares similares